Language

English

Publication Date

1-1-2024

Journal

Frontiers in Psychiatry

DOI

10.3389/fpsyt.2024.1526488

PMID

39935628

PMCID

PMC11811752

PubMedCentral® Posted Date

1-28-2025

PubMedCentral® Full Text Version

Post-print

Abstract

INTRODUCTION: Post-Traumatic Stress Disorder (PTSD) entails behavioral changes with increased risk of suicide, and there is no consensus on the preferred antidepressants for treatment of those PTSD patients who are at elevated risk for suicide.

METHODS: We conducted a clinical trial emulation study comparing suicide-related events (SREs) among those patients' initiating antidepressants within 60 days after a qualifying SRE. Patients were followed from initiation of antidepressant until any of the following: treatment cessation, switching, death, or loss to follow-up. The outcome is a new onset of an SRE.

RESULTS: Citalopram exhibited a significantly fewer case with new SREs compared to other most used antidepressants such as venlafaxine, duloxetine, and mirtazapine-even after adjusting for multiple comparisons and other covariants.

DISCUSSION: Findings suggest potential risks associated with certain antidepressants in the PTSD population, emphasizing cautious prescription considerations.

Keywords

social determinants of health, post-tramatic stress disorder, suicide-related behavior, antidepressant, clinical trial emulation

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.